<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39353281</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice.</ArticleTitle><Pagination><StartPage>105361</StartPage><MedlinePgn>105361</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105361</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2024.105361</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(24)00397-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mouse models that recapitulate key features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are important tools for understanding complex interactions between host genetics, immune responses, and SARS-CoV-2 pathogenesis. Little is known about how predominantly cellular (Th1 type) versus humoral (Th2 type) immune responses influence SARS-CoV-2 dynamics, including infectivity and disease course.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We generated knock-in (KI) mice expressing human ACE2 (hACE2) and/or human TMPRSS2 (hTMPRSS2) on Th1-biased (C57BL/6; B6) and Th2-biased (BALB/c) genetic backgrounds. Mice were infected intranasally with SARS-CoV-2 Delta (B.1.617.2) or Omicron BA.1 (B.1.1.529) variants, followed by assessment of disease course, respiratory tract infection, lung histopathology, and humoral and cellular immune responses.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">In both B6 and BALB/c mice, hACE2 expression was required for infection of the lungs with Delta, but not Omicron BA.1. Disease severity was greater in Omicron BA.1-infected hTMPRSS2-KI and double-KI BALB/c mice compared with B6 mice, and in Delta-infected double-KI B6 and BALB/c mice compared with hACE2-KI mice. hACE2-KI B6 mice developed more severe lung pathology and more robust SARS-CoV-2-specific splenic CD8 T cell responses compared with hACE2-KI BALB/c mice. There were no notable differences between the two genetic backgrounds in plasma cell, germinal center B cell, or antibody responses to SARS-CoV-2.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">SARS-CoV-2 Delta and Omicron BA.1 infection, disease course, and CD8 T cell response are influenced by the host genetic background. These humanized mice hold promise as important tools for investigating the mechanisms underlying the heterogeneity of SARS-CoV-2-induced pathogenesis and immune response.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was funded by NIH U19 AI142790-02S1, the GHR Foundation, the Arvin Gottleib Foundation, and the Overton family (to SS and EOS); Prebys Foundation (to SS); NIH R44 AI157900 (to KJ); and by an American Association of Immunologists Career Reentry Fellowship (FASB).</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Shailendra Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ana-Sosa-Batiz</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timis</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafee</LastName><ForeName>Norazizah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Synbal Inc., 1759 Yorktown Rd., San Mateo, CA, 94402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maule</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Paolla Beatriz Almeida</ForeName><Initials>PBA</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conner</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Synbal Inc., 1759 Yorktown Rd., San Mateo, CA, 94402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentine</LastName><ForeName>Kristen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowley</LastName><ForeName>Dale O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>TransViragen Inc., 109 Mason Farm Road, Chapel Hill, NC, 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Robyn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elong Ngono</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Krithik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Alves</LastName><ForeName>Rúbens Prince</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hastie</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saphire</LastName><ForeName>Erica Ollmann</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webb</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Synbal Inc., 1759 Yorktown Rd., San Mateo, CA, 94402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarnagin</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Synbal Inc., 1759 Yorktown Rd., San Mateo, CA, 94402, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Histopathology Core Facility, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA. Electronic address: kenneth@lji.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shresta</LastName><ForeName>Sujan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA; Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UC San Diego School of Medicine, La Jolla, CA, 92037, USA. Electronic address: sujan@lji.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="Y">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="Y">Th1 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cells</Keyword><Keyword MajorTopicYN="N">BALB/c</Keyword><Keyword MajorTopicYN="N">C57BL/6</Keyword><Keyword MajorTopicYN="N">CD4 T cells</Keyword><Keyword MajorTopicYN="N">CD8 T cells</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Mouse model</Keyword><Keyword MajorTopicYN="N">Omicron BA.1</Keyword><Keyword MajorTopicYN="N">hACE2</Keyword><Keyword MajorTopicYN="N">hTMPRSS2</Keyword></KeywordList><CoiStatement>Declaration of interests CC, NS, and KJ were employees of Synbal, Inc. DOC is employed by and holds stock in TransViragen Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39353281</ArticleId><ArticleId IdType="pmc">PMC11472634</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2024.105361</ArticleId><ArticleId IdType="pii">S2352-3964(24)00397-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159271</ArticleId><ArticleId IdType="pubmed">32014114</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162–177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H., Chan J.F., Yuen T.T., et al. Emerging SARS-CoV-2 variants expand species tropism to murines. eBioMedicine. 2021;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530107</ArticleId><ArticleId IdType="pubmed">34689086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Neerukonda S.N., Wang R., Vassell R., et al. Characterization of entry pathways, species-specific angiotensin-converting enzyme 2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants. J Virol. 2022;96(17)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472608</ArticleId><ArticleId IdType="pubmed">36000843</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett B.J., Grove J., MacLean O.A., et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7(8):1161–1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I., et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706–714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H., Chan J.F., Hu B., et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603(7902):693–699.</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzdorf K., Jacobsen H., Greweling-Pils M.C., et al. TMPRSS2 is essential for SARS-CoV-2 beta and Omicron infection. Viruses. 2023;15(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9961888</ArticleId><ArticleId IdType="pubmed">36851486</ArticleId></ArticleIdList></Reference><Reference><Citation>Villadiego J., García-Arriaza J., Ramírez-Lorca R., et al. Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. Nat Neurosci. 2023;26(2):226–238.</Citation><ArticleIdList><ArticleId IdType="pubmed">36624276</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson S.J., Bedard O., McNally K.L., et al. Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19. Nat Commun. 2023;14(1):4481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368652</ArticleId><ArticleId IdType="pubmed">37491352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Wong L.R., Li K., et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589(7843):603–607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855185</ArticleId><ArticleId IdType="pubmed">33166988</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Lau Y.F., Lamirande E.W., et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812346</ArticleId><ArticleId IdType="pubmed">19906920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.S., Macatonia S.E., O'Garra A., Murphy K.M. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med. 1995;181(2):713–721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191880</ArticleId><ArticleId IdType="pubmed">7836924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills C.D., Kincaid K., Alt J.M., Heilman M.J., Hill A.M. Pillars article: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000. 164: 6166-6173. J Immunol. 2017;199(7):2194–2201.</Citation><ArticleIdList><ArticleId IdType="pubmed">28923981</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A., Paddock C., Vogel L., Butler E., Zaki S., Subbarao K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol. 2005;79(9):5833–5838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1082763</ArticleId><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G., Liu C., Kou Z., et al. Differences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models. PLoS One. 2014;9(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968029</ArticleId><ArticleId IdType="pubmed">24676272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornefett J., Krause J., Klose K., et al. Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain. BMC Microbiol. 2018;18(1):45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977748</ArticleId><ArticleId IdType="pubmed">29848308</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro M.B., Lopes M.E., Hohman L.S., et al. Th1-Th2 cross-regulation controls early leishmania infection in the skin by modulating the size of the permissive monocytic host cell reservoir. Cell Host Microbe. 2020;27(5):752–768.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32298657</ArticleId></ArticleIdList></Reference><Reference><Citation>Corripio-Miyar Y., Hayward A., Lemon H., et al. Functionally distinct T-helper cell phenotypes predict resistance to different types of parasites in a wild mammal. Sci Rep. 2022;12(1):3197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8873199</ArticleId><ArticleId IdType="pubmed">35210503</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative C-HG Mapping the human genetic architecture of COVID-19. Nature. 2021;600(7889):472–477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674144</ArticleId><ArticleId IdType="pubmed">34237774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Cooper-Knock J., Weimer A.K., et al. Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity. Cell Syst. 2022;13(8):598–614.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163145</ArticleId><ArticleId IdType="pubmed">35690068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel A.B., Glickman J.W., Michels J.R., Kim-Schulze S., Miller R.L., Guttman-Yassky E. Th2/Th1 cytokine imbalance is associated with higher COVID-19 risk mortality. Front Genet. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324177</ArticleId><ArticleId IdType="pubmed">34335703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Etayo F.J., Suarez-Fernandez P., Cabrera-Marante O., et al. T-helper cell subset response is a determining factor in COVID-19 progression. Front Cell Infect Microbiol. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952877</ArticleId><ArticleId IdType="pubmed">33718270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Mok B.W.Y., Chen L.L., et al. Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin Infect Dis. 2022;75(1):e822–e826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754807</ArticleId><ArticleId IdType="pubmed">34915551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Jackson L., Khoury D.S., et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni E., Bowen J.E., Rosen L.E., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602(7898):664–670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531318</ArticleId><ArticleId IdType="pubmed">35016195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J., Zhang H., Zhang Y., et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11(1):337–343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Gotz J. Pronuclear injection for the production of transgenic mice. Nat Protoc. 2007;2(5):1206–1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">17546016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Qiu Z., Shao Y., et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 2013;31(8):681–683.</Citation><ArticleIdList><ArticleId IdType="pubmed">23929336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yang H., Shivalila C.S., et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969854</ArticleId><ArticleId IdType="pubmed">23643243</ArticleId></ArticleIdList></Reference><Reference><Citation>Conner C.M., van Fossan D., Read K., et al. A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies. Biochem Pharmacol. 2023;210</Citation><ArticleIdList><ArticleId IdType="pubmed">36870576</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves R., Wang Y.T., Mikulski Z., et al. SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. Antiviral Res. 2023;212</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10027296</ArticleId><ArticleId IdType="pubmed">36940916</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos Alves R.P., Timis J., Miller R., et al. Human coronavirus OC43-elicited CD4(+) T cells protect against SARS-CoV-2 in HLA transgenic mice. Nat Commun. 2024;15(1):787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10817949</ArticleId><ArticleId IdType="pubmed">38278784</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman V.M., Landt O., Kaiser M., et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandersen S., Chamings A., Bhatta T.R. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun. 2020;11(1):6059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695715</ArticleId><ArticleId IdType="pubmed">33247099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland J., Kavanaugh A., Hong L.K., Kadkol S.S. Development and validation of viral load assays to quantitate SARS-CoV-2. J Virol Methods. 2021;291</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883709</ArticleId><ArticleId IdType="pubmed">33600849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber A.D., Osterrieder N., Bertzbach L.D., et al. Standardization of reporting criteria for lung pathology in SARS-CoV-2-infected hamsters: what matters? Am J Respir Cell Mol Biol. 2020;63(6):856–859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7790148</ArticleId><ArticleId IdType="pubmed">32897757</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 2021;40(16)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8365257</ArticleId><ArticleId IdType="pubmed">34159616</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayati A., Kumar R., Francis V., McPherson P.S. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816624</ArticleId><ArticleId IdType="pubmed">33476648</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.S., Chen R.E., Alam F., et al. SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice. J Virol. 2022;96(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754206</ArticleId><ArticleId IdType="pubmed">34668780</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.S., Bailey A.L., Kafai N.M., et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327–1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbiakha B., Ezzatpour S., Buchholz D.W., et al. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. Sci Adv. 2023;9(38):eadj1736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10516498</ArticleId><ArticleId IdType="pubmed">37738347</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladunni F.S., Park J.-G., Pino P.A., et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705712</ArticleId><ArticleId IdType="pubmed">33257679</ArticleId></ArticleIdList></Reference><Reference><Citation>Speranza E., Williamson B.N., Feldmann F., et al. Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. Sci Transl Med. 2021;13(578)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875333</ArticleId><ArticleId IdType="pubmed">33431511</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolp B., Stern M., Ambiel I., et al. SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models. Cell Rep. 2022;38(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795826</ArticleId><ArticleId IdType="pubmed">35134331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarres-Freixas F., Trinite B., Pons-Grifols A., et al. Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants beta, delta and Omicron in transgenic K18-hACE2 and wildtype mice. Front Microbiol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9114491</ArticleId><ArticleId IdType="pubmed">35602059</ArticleId></ArticleIdList></Reference><Reference><Citation>Leist S.R., Dinnon K.H., 3rd, Schafer A., et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell. 2020;183(4):1070–1085.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510428</ArticleId><ArticleId IdType="pubmed">33031744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fokam J., Essomba R.G., Njouom R., et al. Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon. Sci Rep. 2023;13(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10709425</ArticleId><ArticleId IdType="pubmed">38066020</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10(9):927–934.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal A.M., Fernandez-Brando R.J., Bruballa A.C., et al. Differential outcome between BALB/c and C57bl/6 mice after Escherichia coli O157:H7 infection is associated with a dissimilar tolerance mechanism. Infect Immun. 2021;89(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091094</ArticleId><ArticleId IdType="pubmed">33619029</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., et al. Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21(11):1336–1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M.M., Mathew D., Goel R.R., et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133–21342.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J., Dan J.M., Zhang Z., et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science (New York, NY) 2021;374(6566)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542617</ArticleId><ArticleId IdType="pubmed">34519540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo N., Hidaka Y., Kikuchi O., et al. Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. Nat Aging. 2023;3(1):82–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154196</ArticleId><ArticleId IdType="pubmed">37118516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Dai Z., Mo P., et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in wuhan, China: a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 2020;75(9):1788–1795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184388</ArticleId><ArticleId IdType="pubmed">32279081</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon K.H., 3rd, Leist S.R., Schafer A., et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034761</ArticleId><ArticleId IdType="pubmed">32854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Zhuang Z., Zheng J., et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734–743.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7284240</ArticleId><ArticleId IdType="pubmed">32643603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>